Overview
Lobbying Costs
450,000€
Financial year: Jan 2015 - Dec 2015
Lobbyists (Full time equivalent)
1 Fte (2)
Lobbyists with EP accreditation
0
High-level Commission meetings
1
Lobbying Costs over the years
-
Info
Biogen Inc.
EU Transparency Register
966165310889-60 First registered on 26 Mar 2013
Goals / Remit
Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology company and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies.
Main EU files targeted
Biogen interacts with EU institutions and engages on issues relevant to Biogen and to the biopharmaceutical sector to develop a healthcare environment in which all patients have access to the medicines they need; pharmaceutical treatments are integrated into a continuum of care; financial returns attract investment; and the environment enables us to seek new cures for this and future generations. We foster debates around the value of medical innovation and patient access inequalities.
In 2015, we monitored several legislative and non-legislative files including the implementation of the EU Regulation No 536/2014 on clinical trials on medicinal products for human use; the Implementation of the Directive 2011/62/EU amending Directive 2001/83/EC on the Community code relating to medicinal products for human use, as regards the prevention of the entry into the legal supply chain of falsified medicinal products; the implementation of the EU Directive 2014/24/EU on public procurement and repealing Directive 2004/18/EC Text with EEA relevance; the follow-up actions of Council recommendations on an action in the field of rare diseases (2009/C 151/02); the debates and initiatives on international reference pricing of medicines; the European cooperation mechanisms on Health Technology Assessment such as EUnetHTA; the Revision of Medical Device and IVD Regulation; as well as policies related to the prevention and early intervention in Chronic Diseases, Demographic change and healthy ageing, Competition in the pharmaceutical sector .Address
Head Office
225 Binney Street
Cambridge MA 02142
UNITED STATESEU Office
Park Lane G
Culliganlaan 2G
Diegem 1831
BELGIUM -
People
Total lobbyists declared
2
Employment time Lobbyists 50% 2 Lobbyists (Full time equivalent)
1
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
0 accreditations were / are live (in bold) for the selected state of 12 Dec 2016
Name Start date End Date Mr Alessandro Tempra 26 Nov 2021 26 Nov 2022 Mr Andrea Corazza 28 Sep 2021 30 Jul 2022 Mr Andrea Corazza 26 Feb 2020 26 Feb 2021 Ms Andreea Antonovici 17 Jan 2020 01 Feb 2021 Mr Alessandro Tempra 17 Jan 2020 01 Feb 2021 Ms Isabel KLINNERT 20 Jul 2017 15 Jul 2018 Emanuele DEGORTES 27 Jun 2017 19 Jun 2018 Ms Tresja Bolt 23 Jan 2017 23 Jan 2018 Mr Erwan Gicquel 03 Sep 2015 31 Aug 2016 Ms Danuta Rydlewska 03 Sep 2015 31 Aug 2016 Mr Erwan Gicquel 02 Aug 2014 31 Jul 2015 Ms Danuta Rydlewska 02 Aug 2014 31 Jul 2015 Mr Erwan Gicquel 07 Aug 2013 02 Aug 2014 Ms Danuta Rydlewska 07 Aug 2013 02 Aug 2014 Complementary Information
While several Biogen employees contribute to the company’s activities falling under the scope of the Transparency Register, only 2 Biogen employees spent more than 10% of their respective work time in 2015 on this.
Person in charge of EU relations
Ms Tresja Bolt (Director Government Affairs Europe)
Person with legal responsibility
Mr Georges A Scangos (CEO)
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
In 2015 Biogen was a member of EFPIA, EuropaBio, Eucope, Eucomed and AmCham EU
Member organisations
None declared
-
Financial Data
Closed financial year
Jan 2015 - Dec 2015
Lobbying costs for closed financial year
450,000€
Other financial info
The estimated costs of Biogen activities for the year 2015 include staff costs based on the full-time equivalents already declared, payment to third parties (e.g. fees for consultants) and membership and related fees for joining relevant networks and structures (e.g. trade associations). This estimate follows and is consistent with the guidance provided by the European Federation of Pharmaceutical Industries and Associations (EFPIA).
-
EU Structures
Groups (European Commission)
None
ACC
None
Groups (European Parliament)
None
Communication activities
not applicable
Other activities
None declared
Meetings
Meetings
1 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 27 Nov 2015 Location Brussels Subject Biopharmaceutical industry's contribution to jobs and growth Cabinet Cabinet of Vice-President Jyrki Katainen Portfolio Jobs, Growth, Investment and Competitiveness Attending - Grzegorz Radziejewski (Cabinet member)
Other Lobbyists